BullFrog AI (BFRG)
Applies AI-driven biomedical data analysis to drug development.
Something off on this page? Send us feedback.
Applies AI-driven biomedical-data platforms and licensed therapeutic assets to drug development, seeking collaboration, service, milestone and licensing revenue from biopharma and research partners. The platform combines bfPREP, bfLEAP, Data Networks and bfARENAS, while recognized revenue remains concentrated in a completed collaboration.
Applies bfPREP, bfLEAP, BullFrog Data Networks and bfARENAS to complex clinical, multi-omics and real-world data. The platform supports target identification and validation, mechanism-of-action analysis, patient-response subgroup analysis, trial optimization and drug repurposing for biopharma and research partners.
Earns collaboration revenue from analytics projects, with potential service fees, success fees, milestones, intellectual-property rights and eventual licensing economics from drug assets. Reported commercial revenue has come from a completed oncology collaboration; subscription-style Data Networks modules remain an intended recurring-revenue model rather than an audited revenue stream.
Also holds university-licensed oncology and liver-disease programs that are not approved for commercialization. The virtual Maryland operation depends on JHU-APL technology rights, partner relationships, biomedical data access, financing and pharmaceutical regulatory processes.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.9M · Total debt $90.1K · Total assets $7.7M · Shareholders' equity $7.0M
- Revenue
- $215.4K
- Operating income
- −$1.4M
- Net income
- −$1.4M
No dividends on record.
| Institutions21 holders · as of Jun 30, 2026 | 6.36% | 1.18M shares | |
| Insiders5 holders · as of Aug 26, 2025 | 13.01% | 2.41M shares | |
| Otherremainder | 80.63% | 14.95M shares |
18.54M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vininder SinghInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 12.77% | 2.37M | Form 4filed Aug 26, 2025 ↗ |
Citadel Advisors LLCInstitution | 1.95% | 361,546 | 13Fas of Jun 30, 2026 |
J. Safra Sarasin Holding AGInstitution | 0.61% | 113,720 | 13Fas of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.57% | 106,484 | 13Fas of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.57% | 104,928 | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Recursion Pharmaceuticals
Broadest rival in AI-enabled discovery, partnerships, and therapeutic programs.
- Schrödinger
Platform software and collaborative drug-discovery rival for biopharma accounts.
- AbCellera Biologics
Antibody platform rival for biopharma partnerships and oncology assets.
- Relay Therapeutics
Precision-oncology rival for computational discovery and development partners.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BullFrog AI | $0.4800 | −3.94% | $9.1M | — | — | 30.5 | +547.6% |
| Recursion Pharmaceuticals | $3.38 | +0.15% | $1.77B | — | — | 32.3 | −61.8% |
| Schrödinger | $20.71 | −0.79% | $1.56B | — | — | 6.0 | +7.5% |
| AbCellera Biologics | $11.10 | −2.27% | $3.47B | — | — | 52.4 | −76.3% |
| Relay Therapeutics | $18.80 | +1.57% | $4.06B | — | — | 391.9 | −48.3% |
| Median | — | — | 42.4 | −55.0% |